| abstract |
Cpds of formulae (I) and (II), cationic salts of (I) and pharmacologically acceptable non-toxic salts of (II) are new. (where R1CO is acyl). (II) are antibacterials used as 5-200 (pref. 5-20) mg/kg/day (I) are intermediates for (I). Specif claimed (II) are those in which R is benzyl, phenoxymethyl, 2,6-dimethoxyphenyl, alpha-methoxy-3,4-dichlorobenzyl, alpha-acetoxybenzyl or alpha-aminobenzyl. |